EMA starts new benefit-risk assessment of flupirtine

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1677卷 / 1期
关键词：
D O I：
10.1007/s40278-017-38280-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [31] A benefit-risk assessment of caffeine as an analgesic adjuvant
    Zhang, WY
    DRUG SAFETY, 2001, 24 (15) : 1127 - 1142
  • [32] Benefit-risk assessment of raloxifene in postmenopausal osteoporosis
    Cranney, A
    Adachi, JD
    DRUG SAFETY, 2005, 28 (08) : 721 - 730
  • [33] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    Weili He
    Yaxuan Sun
    Qing Li
    Sabrina Wan
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 625 - 634
  • [34] Benefit-risk assessment: industry and regulatory perspectives
    Reactions Weekly, 2001, 882 (1) : 3 - 4
  • [35] Benefit-risk assessment for binary diagnostic tests
    Bai, Tianyu
    Huang, Lan
    Li, Meijuan
    Tiwari, Ram
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (05) : 760 - 775
  • [36] Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis
    Schmidt, H
    Woodcock, BG
    Geisslinger, G
    DRUG SAFETY, 2004, 27 (03) : 185 - 196
  • [37] Benefit-Risk Assessment of Sirolimus in Renal Transplantation
    Dirk R.J. Kuypers
    Drug Safety, 2005, 28 : 153 - 181
  • [38] Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
    Helmut Schmidt
    Barry G. Woodcock
    Gerd Geisslinger
    Drug Safety, 2004, 27 : 185 - 196
  • [39] Bayesian Approach to Personalized Benefit-Risk Assessment
    Cui, Shiqi
    Zhao, Yueqin
    Tiwari, Ram C.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 316 - 324
  • [40] Benefit-risk assessment of sirolimus in renal transplantation
    Kuypers, DRJ
    DRUG SAFETY, 2005, 28 (02) : 153 - 181
12345